“…This strategy is simple, broadly applicable, and improves peptide biostability without altering the backbone and side chain functional groups necessary for full biological activity . Aminopeptidases are the major source of proteolytic activity in most tissues, and their action represents the predominant degradation pathway for peptides containing a free N-terminal amine, even in the presence of an unprotected carboxyl terminus. − Protection of the N-terminus is therefore essential to peptide stability in vivo, and methods such as N-terminal acetylation and methylation have found widespread use. ,− Additionally, our laboratory has observed that N-terminal substitution with α-azido acids, methyl groups, or hydrogen atoms substantially increased peptide biostability, hydrophobicity, and activity in various peptide models without adversely affecting other pharmacokinetic properties. − This suggests that incorporation of appropriate N-terminal modifications may have the potential to improve a greater range of peptide characteristics than currently recognized. However, direct comparisons between N-terminal modifications with respect to a variety of pharmacokinetic (PK a Abbreviations: NT, neurotensin; hNTR1, human neurotensin receptor 1; BBB, blood−brain barrier; Hlys, homolysine; ip, intraperitoneal; MALDI-TOF, matrix-assisted laser desorption ionization time-of-flight; MTBE, methyl- tert -butyl ether; Mtr, 4-methoxy-2,3,6-trimethylbenzenesulfonyl; NN, neuromedin N; NT, neurotensin; NTR, neurotensin receptor; Pbf, 2,2,4,6,7-pentamethylbenzofuran-5-sulfonyl; PK, pharmacokinetic; SAR, structure−activity relationship; X Ps , ( S )-(−)-4-(phenylmethyl)-2-oxazolidinone. ) parameters have not been reported, which is the subject of this report.…”